Kodiak Sciences Inc. (KOD)

Kodiak Sciences’ preliminary results for the second fiscal quarter of 2026 showed EPS trailing consensus, with -$1.05 against the -$0.96 estimate (difference -$0.09), as the clinical-stage retinal-disease developer continued to post losses; the company reported the quarter on August 12, 2026. GAAP net income was a loss of about $65.6 million, down -20.9% year over year from a loss of about $54.3 million, while operating income came in at a loss of roughly $66.8 million. Operating cash flow was negative at about $46.2 million. On a year-over-year basis, EPS of -$1.05 compared with -$1.03 a year ago (down -1.9%). For the next period, consensus calls for EPS of -$0.99.